Halfway through 2016, acquisitions and mergers are an eternal topic in the big health industry. So what are the big mergers and acquisitions in the first half of 2016? This paper takes stock of the top 10 mergers and acquisitions in the first half of 2016 in the field of medical and pharmaceutical health.
NO.1 Shire acquires Baxalta for $32 billion
Industry: Pharmaceutical
Trading status: Successful completion
After six months of negotiations, London drugmaker Shire finally announced plans to acquire Baxalta for $32 billion in cash and share trading, a deal that would make Shire a bigger advantage in treating rare diseases.
But this year has just passed half. A major deal may replace it and become the largest M&A deal of the year – the current German pharmaceutical giant Bayer and its intention to acquire Monsanto are in repeated negotiations. Bayer’s offer to the latter in May was an impressive $62 billion. However, Monsanto rejected the offer, saying that the price was "imperfect and the economic conditions were insufficient." The current negotiations on the deal are still in progress.
NO.2 Abbott Laboratories' $30.6 billion acquisition of St Jude Medical
Industry: Medical Devices & Equipment
Trading status: The transaction is expected to be completed in the fourth quarter of this year.
Abbott Laboratories announced that it will acquire St. Jude Medical in the form of a $25 billion cash and share transaction and assume a net debt of approximately $5.7 billion in St. Jude, or debt refinancing.
This is one of the most sensational M&A deals in the healthcare industry this year, and the combined company will have a stronger medical device business in an increasingly competitive market. The expansion of the scale will also enable Abbott Laboratories to have more market pricing power.
NO.3 IMS Health Holdings merges with Quintiles Transnational Holdings, US$12.8 billion
Industry: Biotechnology
Trading Status: The transaction is expected to be completed in the second half of 2016
CRO giant Quintiles Transnational Holdings agreed to merge with healthcare information company IMS Health as Quintiles IMS.
IMSHealth Chairman and CEO Bo An Rui said in a statement: "This merger addresses the most pressing needs of biotech companies: changing the clinical development of innovative drugs, proving the value of these drugs in the real world, and accelerating commercial success."
Household Supplies,Household Items,Household Goods,Household Mini Electric Appliances
Ningbo Shuangtuo International Trade Co., Ltd. , https://www.nbst-sports.com